drugset / Trial / NCT00082472

Inhaled Doxorubicin Plus IV Docetaxel and Cisplatin in Patients With Non-Small-Cell Lung Carcinoma (NSCLC)

NCT00082472

Phase 1/2 Unknown 30 enrolled Zivena
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is intended to show whether inhaled chemotherapy can be added to a standard IV chemotherapy regime, to investigate the additional toxicities and to show initial evidence of efficacy of the combination.

Timeline

Start
2004-01
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxorubicin Other / unclassified Inhaled
Background Cisplatin Other / unclassified Intravenous
Background Docetaxel Small molecule Intravenous